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OBJECTIVES The purpose of this study was to determine if patients with modest hyperlipidemia, and no
other risk factors for coronary artery disease (CAD), have impaired endothelium-dependent
(ED) vasoactivity.
BACKGROUND Hypercholesterolemia impairs ED vasodilation, but the impact of elevated triglycerides on
endothelial function is not as well established.
METHODS High-resolution ultrasound was used to determine flow-mediated dilation (FMD) in the
brachial artery (BA) after a 5-min arterial occlusion (endothelium-dependent stimulus) and
nitroglycerin-induced dilation (endothelium-independent stimulus). We studied 40 healthy
controls (Group 1), 38 patients with elevated low-density lipoprotein (LDL) cholesterol
(Group 2) and 35 patients with elevated triglycerides (Group 3). Patients were excluded if
they had known CAD or other risk factors for CAD, or if they were receiving lipid-lowering
or vasoactive medications.
RESULTS Control patients (Group 1) had normal LDL cholesterol (2.6 6 0.8 mmol/liter) and
triglyceride levels (1.0 6 0.5 mmol/liter) compared with Group 2 (5.2 6 1.2 mmol/liter,
1.8 6 0.6 mmol/liter) and Group 3 (3.5 6 0.9 mmol/liter, 4.2 6 2.5 mmol/liter) subjects
(p , 0.001). Baseline BA diameters were the same across the three groups. There was no
significant attenuation of flow-mediated vasodilation (FMD) in either of the hyperlipidemic
groups (Group 1: 10.9 6 5.0% vs. Group 2: 8.6 6 6.1% vs. Group 3: 9.4 6 3.9%; p 5 0.14).
However, nitroglycerin-induced vasodilation was mildly reduced (Group 1: 21.0 6 5.0% vs.
16.9 6 7.6% vs. 17.3 6 7.7%; p 5 0.01). By multivariate analysis, after controlling for
baseline diameters, only the ratio of LDL/high-density lipoprotein predicted a minor
impairment in FMD.
CONCLUSIONS In patients free from other cardiac risk factors, modest elevations of triglycerides or LDL
cholesterol do not significantly attenuate BA endothelial-dependent vasodilation. Synergism
with other cardiac risk factors may be required to significantly impair endothelial function in
these patients. (J Am Coll Cardiol 1999;33:2038–43) © 1999 by the American College of
Cardiology
Endothelial dysfunction represents one of the earliest events
in the process of atherosclerosis. The endothelial cell is
important in maintaining vascular integrity through a vari-
ety of mechanisms (1). These protective methods include
vasodilation (2), as well as prevention of platelet aggregation
(3) and smooth muscle proliferation (4). Endothelium-
dependent vasodilation is mediated through the release of
vasodilators such as nitric oxide (NO) (5). In response to
physiologic stimuli, such as shear stress from flowing blood,
the endothelium releases NO, which causes smooth muscle
cell relaxation via an increased concentration of cGMP (6).
Impaired activity of NO is associated with atherosclerosis
and the subsequent development of vascular disease (7).
Impaired endothelium-dependent vasodilation has been
associated with increased cholesterol (8,9), but much less is
known about the role of other lipid subfractions. Hypertri-
glyceridemia is probably an independent risk factor for
coronary artery disease (CAD) (10). Furthermore, elevated
levels of triglycerides are important in modifying the effects
of other lipid subfractions (11,12). Recent data suggest that
low-density lipoprotein (LDL) cholesterol itself is not as
injurious as oxidized LDL in producing impaired endothe-
lial function (13). This effect is mediated through a number
of mechanisms, including impaired synthesis and release of
NO, as well as increased oxidative degradation of NO
(14–16). Elevated triglycerides predict the presence of small
dense LDL particles, which are more susceptible to oxida-
tion, and are particularly prone to produce endothelial
dysfunction (17,18). Thus, we hypothesized that patients
with elevated triglycerides may have impaired endothelial
function.
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The purpose of this study was to examine brachial artery
flow-mediated vasodilation (FMD) in patients with modest
hyperlipidemia and without confounding risk factors for
CAD, in order to determine the effect of triglycerides on
endothelial function.
METHODS
Patients. Patients were prospectively assigned to one of
three groups: Group 1, normal fasting lipid profile (n 5 40),
which was defined as an LDL cholesterol ,3.4 mmol/liter,
and a triglyceride level ,2.2 mmol/liter; Group 2, elevated
LDL cholesterol (n 5 38) which was defined as LDL
cholesterol .4.3 mmol/liter, with a triglyceride level ,2.2
mmol/liter (n 5 38); and Group 3, elevated triglycerides (n
5 35), which was defined as triglycerides .2.2 mmol/liter
with an LDL cholesterol ,4.3 mmol/liter (n 5 35). Groups
2 and 3 were combined to form a hyperlipidemic group to
compare with controls. The study patients were all recruited
from the University of Calgary Lipid Clinic. Group 1,
which formed the control group, consisted of volunteers and
staff. Exclusion criteria for all groups included any other risk
factor for CAD, such as: hypertension, postmenopausal
status, smoking, diabetes mellitus, family history of CAD,
prior history of CAD, peripheral vascular disease, stroke or
family history of a lipid abnormality in greater than two
first-degree relatives. Patients and controls were also ex-
cluded if they were on any vasoactive or lipid-lowering
medications.
Study protocol. Written, informed consent was obtained
from all patients in accordance with the guidelines estab-
lished by the Committee for the Protection of Human
Subjects at our institution. A 7.5-MHz linear phased array
ultrasound transducer (Hewlett-Packard, Andover, Massa-
chusetts) was used to image the dominant arm brachial
artery longitudinally just above the antecubital fossa. After
an overnight fast, and measurement of a lipid profile, all
patients rested for 10 to 15 min in a quiet room at room
temperature. After a baseline image was obtained, a blood
pressure cuff was inflated to 200 mm Hg on the proximal
portion of the arm for 5 min, and then released. The
increased flow in the artery after removal of the blood
pressure cuff is termed reactive hyperemia and results in
FMD (19). Images were obtained for the first 2 min after
cuff deflation. This FMD was used as a measure of
endothelium-dependent vasodilation (20–22). The brachial
artery was then allowed to return to normal (5 min), and
repeat baseline images were obtained. Then, 0.3 mg of
sublingual nitroglycerin was administered, and the brachial
artery was imaged for the ensuing 4 min. The response to
nitroglycerin is a measure of endothelium-independent
vasodilation (23). Blood pressure and heart rate were re-
corded during each stage of the investigation. Pulsed-wave
Doppler was used to determine the flow velocity integral at
each intervention. We have previously used this technique
to detect impaired endothelial function in patients with
known CAD (24).
Analysis. Images were recorded on VHS videotape. Three
sequential systolic frames (taken at the end of the T wave on
the electrocardiogram [ECG]) for each intervention (base-
line, reactive hyperemia, repeat baseline and nitroglycerin)
were digitized and saved to a computer. Previous studies
have shown that maximal arterial dilatation occurs 1 min
after cuff deflation, and 3 min after administration of
nitroglycerin (25). Arterial diameter was determined over a
1-cm straight segment by locally developed software. The
average diameter from each of the three frames was used to
calculate the end point of interest, which was the percent
diameter change of the brachial artery in response to reactive
hyperemia or nitroglycerin. In our laboratory, the intraob-
server and interobserver variability for repeated measure-
ments are 0 6 0.02 and 0.03 6 0.11 mm, respectively.
When reactive hyperemia studies are performed on two
separate days, the mean difference in brachial vasodilator
response in absolute terms is 3.1 6 2.9%.
Flow. Brachial artery blood flow was calculated as:
Flow ~ml/min! 5 velocity 3 HR 3 ~diameter2/4! 3 p 3 0.006
Statistics. Differences between clinical characteristics, and
brachial artery vasodilator responses, were evaluated and
analyzed by unpaired t tests for two-group comparisons and
one-way analysis of variance with a Bonferroni correction
for multiple group comparisons. Predictors of brachial artery
vasodilator responses to reactive hyperemia were obtained
by univariate analysis. Those with a p value ,0.05 were
entered into a multivariate regression model using the Systat
software program (Evanston, Illinois). Previous studies have
demonstrated that the percent brachial artery diameter
change to reactive hyperemia is inversely correlated with the
baseline diameter and, as such, this variable was included in
the step-wise model (25). Statistical significance was de-
fined as a two-sided p value , 0.05. All data are expressed
as the mean value 6 SD. We calculated that by using 35
patients, our study had an 80% power to detect a statistically
significant 2.5% decrease in FMD, assuming a standard
deviation of 4%.
RESULTS
Subjects. The clinical characteristics and lipid profiles of
the study patients are summarized in Table 1. The control
Abbreviations and Acronyms
CAD 5 coronary artery disease
ECG 5 electrocardiogram
FMD 5 flow-mediated vasodilation
HDL 5 high-density lipoprotein
LDL 5 low-density lipoprotein
NO 5 nitric oxide
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group was younger than the study population, and the
triglyceride group had more men than the other two groups;
otherwise, because of the rigid exclusion criteria, the groups
were well matched. The differences in the primary lipid
subfractions between each group were statistically signifi-
cant.
Brachial artery vasodilation. The change in brachial artery
diameter in response to reactive hyperemia in all patients
ranged from 21% to 25%. As has been reported before,
there is a significant inverse relation between the degree of
dilation and the baseline brachial artery diameter (r 5 0.29;
p 5 0.002). There was no difference in baseline vessel
diameter between the three groups in our study.
There was a trend for mild attenuation of endothelial-
mediated vasodilation in the combined hyperlipidemic
group when compared with controls (9.0 6 5.1% vs. 10.9 6
5.0%, p 5 0.06) (Fig. 2). When evaluated by primary lipid
abnormality, there was no difference in brachial artery
vasodilator response to reactive hyperemia between the
three groups (10.9 6 5.0% vs. 8.6 6 6.1% vs. 9.4 6 3.9%,
respectively, p 5 0.14) (Fig. 1). There was a similar trend
for attenuation of the brachial artery response to nitroglyc-
erin (p 5 0.01) (Fig. 1). These results suggest that there was
no significant impairment of endothelium-dependent vaso-
motor function in this population of patients, but there may
be some mild disruption of endothelium-independent va-
sodilation.
Flow data. There was no difference in brachial artery flow
at baseline or in response to reactive hyperemia between the
three groups (Fig. 3).
Predictors of FMD. Since neither LDL cholesterol nor
triglycerides predicted impaired endothelial function, the
roles of other lipid subfractions were evaluated using a
univariate linear regression analysis. The factors predicting
an attenuated brachial artery response to reactive hyperemia
were a larger baseline diameter, an increased ratio of either
LDL/high-density lipoprotein (HDL) or total cholesterol/
HDL and a reduced level of HDL. Because there was a
difference between the groups with respect to age, we
assessed the impact of age on FMD. No relationship was
found. Triglycerides did not predict impaired endothelial
response. In a multivariate linear regression analysis, when
controlling for baseline brachial artery diameter, only the
ratio of LDL/HDL cholesterol remained a statistically
significant predictor of impaired endothelium function (p 5
0.04) (Table 2).
DISCUSSION
Endothelium-dependent FMD is not significantly impaired
in the brachial artery of patients with modest elevations of
Figure 1. Percent change in brachial artery diameter in response to
reactive hyperemia (RH) and sublingual nitroglycerin (NTG) in
Group 1 (solid bars), and in the combination of Groups 2 and 3
(hatched bars). *p 5 0.06, **p 5 0.01.
Figure 2. Percent change in brachial artery diameter in response to
reactive hyperemia (RH), and sublingual nitroglycerin (NTG) in
Group 1 (solid bars), Group 2 (open bars) and Group 3 (hatched
bars). *p 5 0.14; **p 5 0.05.
Table 1. Patient Characteristics
Group 1
(n 5 40)
Group 2
(n 5 38)
Group 3
(n 5 35) p
Gender (male/female) 28:12 24:14 29:6
Age (years) 32.5 6 7.9 40.4 6 11.2 44.9 6 10.7 , 0.05
Baseline SBP (mm Hg) 114 6 10 117 6 9 125 6 13 NS
Baseline DIA (mm) 3.5 6 0.7 3.6 6 0.7 3.7 6 0.6 NS
Cholesterol (mmol/liter) 4.4 6 0.9 7.2 6 1.3 6.3 6 0.9 , 0.001
LDL (mmol/liter) 2.6 6 0.8 5.2 6 1.2 3.5 6 0.9 , 0.001
Triglycerides (mmol/liter) 1.0 6 0.5 1.8 6 0.6 4.2 6 2.5 , 0.001
HDL (mmol/liter) 1.3 6 0.3 1.1 6 0.3 0.9 6 0.2 , 0.001
Cholesterol: HDL (mmol/liter) 3.6 6 1.2 6.7 6 1.7 7.6 6 2.4 , 0.001
DIA 5 diameter; HDL 5 high-density lipoprotein; LDL 5 low-density lipoprotein; SBP 5 systolic blood pressure.
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triglycerides or LDL cholesterol without other risk factors
for CAD.
Triglycerides. Controversy exists as to the role of hyper-
triglyceridemia as an independent risk factor for CAD.
Triglycerides enhance the catabolism of HDL particles.
Furthermore, they promote the formation of small dense
LDL particles, and facilitate their oxidation and migration
into the arterial wall (26). Much of the association between
triglycerides and CAD in large population studies disap-
pears in a multivariate analysis when controlling for HDL
cholesterol (27). Recently, however, a large study has shown
triglycerides to be an independent risk factor for CAD, even
when controlling for HDL (10). Furthermore, two large
studies have shown a synergistic affect of triglycerides on the
ratio of LDL/HDL cholesterol to predict the incidence of
CAD (11,12).
The effect of hypertriglyceridemia on endothelial func-
tion has been previously assessed in the brachial artery in
small studies with conflicting results (28–30). Vogel et al.
(30) and Lundman et al. (28) used a high-fat meal and an
infusion of a triglyceride emulsion, respectively, to induce
transient hypertriglyceridemia. Both of these studies found
an impaired endothelial response in the brachial artery. Our
study, and that of Chowienczyk et al. (29), used fasting lipid
samples to determine triglyceride levels, and did not find
impaired endothelial function. Also, patients were studied
in the fasting state. Thus, postprandial triglyceride levels
may be important for determining risk of impaired endo-
thelial function. It is interesting to note that, as in our study,
Lundman et al. (28) also found some impairment of
endothelium-independent vasomotion, suggesting that tri-
glyceridemia may interfere with brachial artery smooth
muscle function.
LDL cholesterol. There was no significant deleterious
effect of elevated LDL cholesterol on endothelial function
in the brachial artery in our study, which evaluated patients
with modest hyperlipidemia and no other risk factors for
CAD. This is in contrast to previous studies using this
technique to assess the effect of elevated cholesterol on
endothelial function (31,32). Sorensen et al. (31) found that
FMD was impaired in hypercholesterolemic children when
compared with controls (1.2 6 0.4% vs. 7.5 6 0.7%,
respectively). However, this relationship disappeared when
controlling for lipoprotein(a) (31). In another study, Clark-
son et al. (32) found that FMD was impaired at baseline in
27 subjects with hypercholesterolemia, which improved
after four weeks of treatment with L-arginine (1.7 6 1.3%
vs. 5.6 6 3.0%, respectively). However, 17 of 27 subjects in
the latter study had familial hypercholesterolemia and
marked elevations in total or LDL cholesterol. Other
studies have found oxidized LDL to be a better predictor of
impaired endothelial function (17). In patients with hyper-
cholesterolemia, conditions such as smoking and diabetes,
which increase oxidative stress, are associated with greater
endothelial dysfunction (33,34). For example, Celermajer et
al. (35) found, in a large study, that cholesterol alone did not
predict impaired endothelial function, but became signifi-
cant when smoking status was taken into account. Further-
more, in a study evaluating the effects of cholesterol-
lowering and antioxidant therapy in patients with elevated
cholesterol and CAD, the greatest improvement in endo-
thelial function occurred in patients treated with both a
cholesterol-lowering drug and an antioxidant (36).
Hypercholesterolemia has been shown in large epidemi-
ological studies to increase the risk for CAD (37,38).
Although LDL lowering has been shown to decrease
cardiac morbidity and mortality in primary prevention trials,
the benefits are relatively modest in patients with hypercho-
lesterolemia and no other cardiac risk factors (39). When
combined, these results and our findings suggest that
hypercholesterolemia alone has only a mild detrimental
effect on vascular function and the subsequent development
of atherosclerosis.
HDL. Low levels of HDL cholesterol have been associated
with impaired endothelial function in other studies (40).
Although we found that HDL cholesterol was inversely
related to endothelial function in a univariate model, this
relationship disappeared in a multivariate model. Using a
multivariate model, we found that the ratio of LDL/HDL
cholesterol was a statistically significant, but minor, predic-
tor of impaired endothelial function (p 5 0.04, r2 5 0.121).
It is likely that lipid subfractions, other than LDL, are
important predictors of endothelial function.
Study limitations. Triglycerides were not correlated with
impaired endothelial function in our study. However, we
Figure 3. Change in brachial artery flow at baseline and in
response to reactive hyperemia (RH) in Group 1 (solid bars),
Group 2 (open bars) and Group 3 (hatched bars). There was no
difference in brachial artery flow between groups.
Table 2. Multivariate Model* for Predictors of Impaired
Endothelial Function in the Brachial Artery
Variable
Regression
Coefficient
p
Value
Baseline diameter 20.02 0.005
LDL/HDL 20.006 0.04
*Multiple r value 5 0.35. HDL 5 high-density lipoprotein; LDL 5 low-density
lipoprotein.
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used fasting lipid samples to determine triglyceride levels in
our study population. Postprandial triglyceride levels may be
a better predictor of risk for CAD, and thus, may also be
associated with altered endothelial vasoactivity (41). Like-
wise, we did not assess particle size or the susceptibility of
LDL oxidation, both of which are prone to induce endo-
thelial dysfunction and may have altered our findings (18).
In addition, LDL was calculated using the Freidwald
equation. This is inaccurate when triglyceride levels are
above 5 mmol/liter (6/35 patients). This may have intro-
duced a small systematic error in the hypertriglyceridemic
group.
The effects of impaired endothelial function are most
clinically significant in the coronary circulation. We studied
FMD in the brachial artery, a large peripheral conduit
artery. A close relation between endothelial function in the
coronary and peripheral circulations has been shown to exist
(42). Nonetheless, although endothelial dysfunction is a
systemic process, it may affect conduit and resistance arteries
to a different degree.
Finally, there was a trend toward an impaired response of
the brachial artery to nitroglycerin in Groups 2 and 3,
suggesting that some of the deleterious effects of hyperlip-
idemia may be mediated by altered smooth muscle activity,
rather than entirely by endothelial dysfunction. This has
been demonstrated in two previous studies of hyperlipid-
emia and vascular reactivity (8,28). Regardless, we were
unable to demonstrate a major impairment of either
endothelium-dependent, or endothelium-independent, va-
somotor function in this population of patients.
Conclusions. Modest elevations of triglycerides or LDL
cholesterol are not associated with impaired endothelial
function in the brachial artery of patients free from other
risk factors for CAD. Synergism with other risk factors may
be required to significantly impair vascular function.
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